Melanoma Therapeutics Market, By Therapy Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Adjuvant Therapy, and Combination Therapies), By Disease Stage, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4307
|
Published Date
August 2025
|
Pages
260
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
The melanoma therapeutics market size was valued at US$ 6,701.29 Million in 2024, expanding at a CAGR of 10.50% from 2025 to 2032.
The Melanoma Therapeutics Market is experiencing strong growth, driven by rising skin cancer incidence, greater awareness of early diagnosis, and advancements in immunotherapy and targeted treatments. The demand for checkpoint inhibitors, such as PD-1 and CTLA-4 blockers, is fueling the market due to their proven effectiveness in significantly improving patient survival rates. According to the World Health Organization, skin cancer accounts for over 1 million cases globally each year, with melanoma responsible for the majority of skin cancer deaths, highlighting the urgent need for effective therapies. However, challenges such as high treatment costs and therapy-related side effects continue to impact adoption. Key opportunities exist in personalized medicine, combination therapies, and expanding healthcare expenditure in emerging markets. Additionally, regulatory support and ongoing clinical trials worldwide are fostering continuous innovation. Overall, the market is rapidly evolving, with promising potential for future breakthroughs in melanoma treatment.
Melanoma Therapeutics Market- Market Dynamics
Rising global incidence of cancer cases
The rising global incidence of melanoma is a major factor driving growth in the melanoma therapeutics market. According to the World Health Organization (WHO), the rates of skin cancer have been increasing steadily, fueled by factors such as heightened UV exposure, the popularity of indoor tanning, and the ongoing depletion of the ozone layer. In 2022 alone, approximately 330,000 new cases of melanoma were diagnosed globally, with nearly 60,000 related deaths. Countries like Australia and the United States report some of the highest per capita melanoma rates, resulting in a growing demand for effective treatment options.
This alarming trend has prompted healthcare systems and pharmaceutical companies to invest heavily in early detection tools and innovative therapies. Immunotherapies such as pembrolizumab (Keytruda) and nivolumab have become widely used, showing significant improvements in patient survival rates. Additionally, growing public awareness, widespread screening initiatives, and the rise of routine skin checks are further increasing the demand for more targeted, efficient, and personalized treatments.
Melanoma Therapeutics Market- Segmentation Analysis:
The Global Melanoma Therapeutics Market is segmented on the basis of Therapy Type, Disease Stage, Route of Administration , Distribution Channel, End User, and Region.
The melanoma treatment market is segmented into six key therapy types: Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Adjuvant Therapy, and Combination Therapies. Among these, immunotherapy holds the largest market share due to its superior efficacy and improved survival outcomes, particularly in patients with advanced or metastatic melanoma. Immune checkpoint inhibitors, such as pembrolizumab (Keytruda), have demonstrated significantly better clinical outcomes compared to traditional chemotherapy. This has led to their widespread approval as a first-line treatment in many countries. The increasing use of immunotherapies—both as monotherapies and in combination with other treatment modalities—has positioned them at the center of modern melanoma treatment protocols. According to the National Cancer Institute (NCI), melanoma incidence in the U.S. has increased over recent decades, with over 100,000 new cases expected in 2025, driving demand for innovative therapies like immunotherapy that offer durable responses and improved quality of life.
From the perspective of end users, the market is categorized into Hospitals, Research & Academic Institutes, and Oncology Clinics. Among these, hospitals dominate the market owing to their extensive infrastructure, access to cutting-edge diagnostic tools, and multidisciplinary oncology teams capable of handling complex melanoma cases. Leading medical centers such as Mayo Clinic (USA) and AIIMS (India) routinely offer immunotherapy treatments, including checkpoint inhibitors like pembrolizumab, and conduct advanced surgical interventions. Hospitals are also primary centers for clinical trials and the implementation of emerging therapies. Furthermore, the increasing global burden of cancer is leading to a rise in hospital admissions. According to the World Health Organization (WHO), cancer accounted for nearly 10 million deaths globally in 2022, and melanoma remains one of the most aggressive skin cancers. In response, governments worldwide are significantly increasing healthcare investments in oncology infrastructure, further reinforcing hospitals as the dominant end-user segment in the melanoma treatment market.
Melanoma Therapeutics Market- Geographical Insights
North America holds the largest share of the global melanoma therapeutics market, driven by high levels of awareness, a well-established healthcare infrastructure, and early adoption of advanced treatment options. The United States leads the region, with over 100,000 new melanoma cases reported annually, according to the American Cancer Society. The widespread availability of FDA-approved immunotherapies such as Keytruda (pembrolizumab) and Opdivo (nivolumab), coupled with strong reimbursement policies, enhances treatment accessibility and patient uptake.
Europe follows closely behind, with countries like Germany and the United Kingdom investing significantly in oncology research, clinical trials, and public health campaigns. Meanwhile, the Asia-Pacific region is poised to experience the fastest growth, driven by rising healthcare expenditure, increasing incidence of skin cancer, and growing access to innovative therapies in countries such as Australia and Japan. Australia, in particular, has one of the world’s highest melanoma incidence rates due to high UV exposure, which has prompted widespread public health initiatives and screening programs. Regional market dynamics are shaped by factors such as disease burden, regulatory frameworks, healthcare infrastructure, and treatment affordability.
Melanoma Therapeutics Market- Competitive Landscape:
The melanoma therapeutics market is highly competitive and innovation-driven, particularly in the areas of immunotherapy and targeted treatment. Key industry players such as Merck & Co., Bristol-Myers Squibb, and Novartis dominate the market with successful drugs like Keytruda and Opdivo, both of which have demonstrated strong clinical efficacy in treating advanced melanoma. Breakthrough developments continue to reshape the landscape. Immunocore gained regulatory approval for KIMMTRAK, the first treatment specifically for uveal melanoma, while Iovance Biotherapeutics received FDA approval for Amtagvi, its T-cell therapy for melanoma.
In October 2024, the UK launched a major initiative called MANIFEST, a £21.9 million research consortium funded by the government and industry partners. The initiative aims to study tumor biomarkers and immune responses from 6,000 cancer patients—including those with melanoma—to understand poor immunotherapy response and improve future treatment strategies. Emerging biotech firms such as BioNTech, Replimune, and RyboDyn are actively advancing next-generation immunotherapies. Strategic collaborations with academic institutions, cancer research centers, and pharma giants are accelerating drug development and clinical trials. Continuous R&D remains central to the market, with efforts focused on increasing treatment efficacy, minimizing side effects, and overcoming drug resistance. These developments are crucial for expanding the therapeutic pipeline and addressing unmet medical needs in melanoma care.
Recent Developments
- April 2025: Immunai and the Parker Institute for Cancer Immunotherapy partnered to build the world’s largest single-cell dataset from cancer patients undergoing immunotherapy. The initiative, powered by PICI’s RADIOHEAD cohort, aims to uncover immune response mechanisms using AI and multi-omic profiling to enhance precision medicine in cancers like melanoma.
- May 2025: RyboDyn expanded its strategic partnership with Moffitt Cancer Center to accelerate development of immunotherapies targeting previously uncharacterized proteins in the “dark proteome.” Using its AI-powered RyboCypher™ platform, RyboDyn will validate Dark Targets™ across tumor types, aiming to create scalable, tumor-specific therapies with broad clinical impact.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MELANOMA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Bristol-Myers Squibb Company
- BioNTech SE
- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Iovance Biotherapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Immunocore Holdings plc
- Others
GLOBAL MELANOMA THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Radiation Therapy
- Adjuvant Therapy
- Combination Therapies
GLOBAL MELANOMA THERAPEUTICS MARKET, BY DISEASE STAGE- MARKET ANALYSIS, 2019 - 2032
- Early-stage Melanoma (Stage 0–II)
- Metastatic Melanoma (Stage IV)
- Regional Melanoma (Stage III)
- Recurrent Melanoma
GLOBAL MELANOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Oral
- Topical
- Injectable (Intravenous, Intralesional)
GLOBAL MELANOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
GLOBAL MELANOMA THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Research & Academic Institutes
- Oncology Clinics
GLOBAL MELANOMA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Melanoma Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Melanoma Therapeutics Market Snippet by Therapy Type
2.1.2. Melanoma Therapeutics Market Snippet by Disease Stage
2.1.3. Melanoma Therapeutics Market Snippet by Route of Administration
2.1.4. Melanoma Therapeutics Market Snippet by Distribution Channel
2.1.5. Melanoma Therapeutics Market Snippet by End User
2.1.6. Melanoma Therapeutics Market Snippet by Country
2.1.7. Melanoma Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Melanoma Therapeutics Key Market Trends
3.1. Melanoma Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Melanoma Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Melanoma Therapeutics Market Opportunities
3.4. Melanoma Therapeutics Market Future Trends
4. Melanoma Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Melanoma Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Melanoma Therapeutics Market Landscape
6.1. Melanoma Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Melanoma Therapeutics Market – By Therapy Type
7.1. Overview
7.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
7.1.2. Immunotherapy
7.1.3. Targeted Therapy
7.1.4. Chemotherapy
7.1.5. Radiation Therapy
7.1.6. Adjuvant Therapy
7.1.7. Combination Therapies
8. Melanoma Therapeutics Market – By Disease Stage
8.1. Overview
8.1.1. Segment Share Analysis, By Disease Stage, 2024 & 2032 (%)
8.1.2. Early-stage Melanoma (Stage 0–II)
8.1.3. Metastatic Melanoma (Stage IV)
8.1.4. Regional Melanoma (Stage III)
8.1.5. Recurrent Melanoma
9. Melanoma Therapeutics Market – By Route of Administration
9.1. Overview
9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
9.1.2. Oral
9.1.3. Topical
9.1.4. Injectable (Intravenous, Intralesional)
10. Melanoma Therapeutics Market – By Distribution Channel
10.1. Overview
10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
10.1.2. Hospital Pharmacies
10.1.3. Online Pharmacies
10.1.4. Retail Pharmacies
11. Melanoma Therapeutics Market – By End User
11.1. Overview
11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
11.1.2. Hospitals
11.1.3. Research & Academic Institutes
11.1.4. Oncology Clinics
12. Melanoma Therapeutics Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Melanoma Therapeutics Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Melanoma Therapeutics Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Melanoma Therapeutics Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Melanoma Therapeutics Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Melanoma Therapeutics Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Disease Stage, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Melanoma Therapeutics Industry
13.1. Competitive Dashboard
13.1.1. Competitive Benchmarking
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. Merck & Co., Inc.
13.2.2. Eisai Co., Ltd.
13.2.3. Bristol-Myers Squibb Company
13.2.4. BioNTech SE
13.2.5. Novartis AG
13.2.6. Pfizer Inc.
13.2.7. Amgen Inc.
13.2.8. Iovance Biotherapeutics, Inc.
13.2.9. F. Hoffmann-La Roche Ltd.
13.2.10. Immunocore Holdings plc
13.2.11. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
